Adam Mader

“A multi-part question for me on the Epioxa launch. We'd just love to get more color on the launch itself and hopefully some metrics.”

“I wanted to ask about EUP 2.0 and specifically one of the offsets, potential offsets for sensing instruments. And if I heard correctly, it doesn't sound like there's any offset assumed in the 300 to 500 basis point headwind for these.”

“Mike, thank you for taking the questions. A couple from me, and maybe we can just start on the CAF side of the business. You know, so the first original Seaguard delivery system approval timing for U.S., if I heard correctly, was Q4.”

“I'll keep it to one multi-part question. In the press release, you talked about moving beyond a single product line company into kind of, I think, a true platform was the phrase you used.”

“Yes, a couple of different places I could take this, but I'll ask one on glaucoma, one on dry eye. Just maybe starting with glaucoma, you know, would love just to kind of better understand the interventional glaucoma market dynamics.”